as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹2,344.7
Change
+9.9 (0.42%)
Open
₹2,337.5
Prev. Close
₹2,334.8
Day High
₹2,374.4
Day Low
₹2,321.5
Volume Analysis
Traded
107,206
Delivered
61,741
Delivery %
57.59%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (20.1%)
- •Strong operating margin (20.0%)
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (18.4%)
- •Strong 3-year revenue growth (15.4%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹2,425.14 | ₹2,399.77 | ₹2,372.24 | ₹2,346.87 | ₹2,319.34 | ₹2,293.97 | ₹2,266.44 |
| Fibonacci | ₹2,399.77 | ₹2,379.56 | ₹2,367.08 | ₹2,346.87 | ₹2,326.66 | ₹2,314.18 | ₹2,293.97 |
| Camarilla | ₹2,359.25 | ₹2,354.4 | ₹2,349.55 | ₹2,346.87 | ₹2,339.85 | ₹2,335.0 | ₹2,330.15 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+67.26%
1 Week
+1.31%
1 Month
+33.59%
3 Months
+25.86%
6 Months
+36.83%
1 Year
+72.19%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹556.22
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
18.47%
Net margin 10.68% × asset turnover 0.91x × equity multiplier 1.9x
Company Overview
Sector
Healthcare
Market Cap
₹44,370 Cr
P/E (TTM)
39.9
ROE
20.1%
Book Value
₹282.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.
TopFund Analysis
Emcure Pharmaceuticals L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (98/100), while Valuation (7/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (20.1%); strong operating margin (20.0%). Strong 3-year EPS growth (18.4%).
TopFund Score — Fundamentals Quality
69/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 8.30 times its book value
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
JM Financial Annual India Conference on November 16, 2026 cancelled due to management unavailability.
Emcure Q2 FY27 call: revenue rose 24% to ₹2,820 crore; FY27 growth outlook raised above 20%.
Intimation of schedule of Analyst/Investor Meeting dated Monday, November 16, 2026
Intimation of schedule of Analyst/Investor Meeting on Monday, November 16, 2026
Newspaper Publication of Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2026
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,663 | 1,668 | 1,771 | 1,815 | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 | 2,363 | 2,470 | 2,580 | 2,820 |
| Expenses + | 1,334 | 1,374 | 1,460 | 1,479 | 1,621 | 1,608 | 1,714 | 1,684 | 1,794 | 1,871 | 1,990 | 2,048 | 2,233 |
| Operating Profit | 329 | 294 | 311 | 336 | 381 | 355 | 402 | 417 | 475 | 493 | 480 | 532 | 588 |
| OPM % | 20.0% | 18.0% | 18.0% | 19.0% | 19.0% | 18.0% | 19.0% | 20.0% | 21.0% | 21.0% | 19.0% | 21.0% | 21.0% |
| Other Income + | -2 | 22 | 12 | 23 | 36 | 4 | -6 | 0 | 3 | -36 | 14 | 2 | 3 |
| Interest | 59 | 61 | 65 | 59 | 46 | 32 | 39 | 27 | 33 | 38 | 46 | 32 | 36 |
| Depreciation | 70 | 84 | 91 | 94 | 97 | 97 | 97 | 99 | 105 | 105 | 106 | 110 | 110 |
| Profit before tax | 198 | 171 | 167 | 207 | 273 | 230 | 261 | 291 | 341 | 314 | 341 | 394 | 446 |
| Tax % | 26.0% | 30.0% | 27.0% | 26.0% | 26.0% | 32.0% | 24.0% | 26.0% | 26.0% | 26.0% | 29.0% | 26.0% | 27.0% |
| Net Profit + | 146 | 120 | 121 | 153 | 202 | 156 | 197 | 215 | 251 | 231 | 244 | 292 | 325 |
| EPS in Rs | 8 | 6 | 6 | 8 | 10 | 8 | 10 | 11 | 13 | 12 | 13 | 16 | 17 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | 17 | 20 | 18 | 19 | 16 | 13 | 20 | 17 | 23 | 24 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 4,717 | 5,049 | 5,033 | 5,855 | 5,986 | 6,658 | 7,896 | 9,204 | 10,234 |
| Expenses + | 3,968 | 4,340 | 3,817 | 4,525 | 4,804 | 5,429 | 6,427 | 7,458 | 8,141 |
| Operating Profit | 749 | 708 | 1,216 | 1,330 | 1,182 | 1,230 | 1,469 | 1,746 | 2,093 |
| OPM % | 16.0% | 14.0% | 24.0% | 23.0% | 20.0% | 18.0% | 19.0% | 19.0% | 20.0% |
| Other Income + | 72 | -25 | -159 | 63 | 39 | 47 | 62 | 100 | -17 |
| Interest | 223 | 257 | 155 | 176 | 214 | 237 | 176 | 144 | 152 |
| Depreciation | 267 | 321 | 250 | 245 | 260 | 312 | 384 | 415 | 430 |
| Profit before tax | 331 | 105 | 652 | 973 | 747 | 727 | 971 | 1,287 | 1,494 |
| Tax % | 37.0% | 4.0% | 36.0% | 28.0% | 25.0% | 27.0% | 27.0% | 27.0% | — |
| Net Profit + | 209 | 101 | 419 | 703 | 562 | 528 | 707 | 941 | 1,093 |
| EPS in Rs | 11 | 5 | 23 | 37 | 29 | 28 | 36 | 49 | 58 |
| Dividend Payout % | 32.0% | 54.0% | 4.0% | 8.0% | 7.0% | 7.0% | 8.0% | 7.0% | — |
| Sales growth | — | 7 | 0 | 16 | 2 | 11 | 19 | 17 | 21 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Reserves | 1,654 | 1,731 | 2,092 | 1,807 | 2,320 | 2,771 | 4,257 | 4,760 | 5,154 |
| Borrowings + | 2,128 | 2,327 | 2,310 | 2,217 | 2,334 | 2,335 | 1,023 | 1,521 | 1,791 |
| Other Liabilities + | 1,613 | 1,721 | 2,184 | 1,816 | 1,798 | 2,422 | 2,653 | 3,043 | 3,029 |
| Total Liabilities | 5,577 | 5,960 | 6,768 | 6,021 | 6,634 | 7,709 | 8,122 | 9,514 | 10,164 |
| Fixed Assets + | 2,247 | 2,382 | 2,188 | 2,044 | 2,147 | 3,125 | 3,197 | 3,319 | 3,372 |
| CWIP | 581 | 485 | 302 | 320 | 411 | 159 | 177 | 273 | 328 |
| Investments | 0 | 0 | 0 | 25 | 25 | 318 | 95 | 20 | 20 |
| Other Assets + | 2,749 | 3,093 | 4,278 | 3,632 | 4,050 | 4,108 | 4,652 | 5,903 | 6,444 |
| Total Assets | 5,577 | 5,960 | 6,768 | 6,021 | 6,634 | 7,709 | 8,122 | 9,514 | 10,164 |
| Equity Capital | 181 | 181 | 181 | 181 | 181 | 181 | 189 | 190 | 190 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 444 | 500 | 704 | 768 | 747 | 1,097 | 852 | 944 |
| Cash from Investing Activity + | -409 | -168 | -256 | -574 | -468 | -715 | -96 | -1,175 |
| Cash from Financing Activity + | -735 | -301 | -189 | -152 | -145 | -164 | -814 | 343 |
| Net Cash Flow | -700 | 32 | 259 | 42 | 134 | 219 | -58 | 112 |
| Free Cash Flow | 39 | 362 | 571 | 349 | 345 | 801 | 475 | 400 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 77 | 84 | 74 | 81 | 80 | 107 | 75 | 75 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Public | 15.05% | 15.15% | 15.58% | 16.39% | 14.46% | 12.43% | 12.69% | 8.84% | 8.75% |
| Promoters | 78.08% | 77.94% | 77.92% | 77.92% | 77.88% | 77.87% | 77.87% | 77.83% | 77.82% |
| FII | 2.91% | 3.05% | 3.06% | 2.86% | 3.29% | 3.59% | 3.35% | 4.87% | 4.94% |
| DII | 3.96% | 3.87% | 3.44% | 2.84% | 4.36% | 6.1% | 6.1% | 8.46% | 8.49% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Emcure Pharmaceuticals L (this stock) | 44,370 | 39.9 | 8.29 | 20.1% |
| Glaxosmithkline Pharma Lt | 45,576 | 40.2 | 24.22 | 45.6% |
| Ipca Laboratories Ltd | 46,508 | 32.3 | 5.36 | 15.7% |
| Ajanta Pharma Limited | 41,393 | 32.8 | 8.51 | 27.1% |
| Global Health Limited | 38,864 | 60.0 | 8.97 | 15.2% |
| Sai Life Sciences Limited | 38,018 | 99.5 | 14.08 | 15.4% |
| Narayana Hrudayalaya Ltd. | 37,889 | 41.8 | 7.57 | 20.5% |
Which Mutual Funds Hold Emcure Pharmaceuticals L?
Frequently Asked Questions about Emcure Pharmaceuticals L
Emcure Pharmaceuticals L (EMCURE) closed at ₹2,344.7 on NSE on 19 November 2026, up 9.9 (0.42%) from the previous close.
Emcure Pharmaceuticals L trades on the NSE (National Stock Exchange of India) under the symbol EMCURE.
Emcure Pharmaceuticals L has a trailing twelve-month P/E (price-to-earnings) ratio of 39.9.
Emcure Pharmaceuticals L has a dividend yield of 0.15%.
Emcure Pharmaceuticals L's 52-week high is ₹2,430.0 and its 52-week low is ₹1,312.0.
Emcure Pharmaceuticals L has a market capitalisation of ₹44,370 crore.
Emcure Pharmaceuticals L has a TopFund Quality Score of 69/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Emcure Pharmaceuticals L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.